摘要
目的研究孟鲁司特联合舒利迭治疗咳嗽变异性哮喘的临床疗效。方法选择2013年10月到2014年10月收治的96例咳嗽变异性哮喘患者,按随机数字表法分成观察组和对照组各48例。观察组给予孟鲁司特联合舒利迭进行治疗,对照组给予吸入舒利迭进行治疗,治疗后一个月对比分析两组患者的临床疗效。结果两组临床疗效比较差异有统计学意义(P<0.01),观察组的疗效显著优于对照组。观察组患者临床症状缓解时间和症状消失时间均显著短于对照组(P<0.01)。结论孟鲁司特联合舒利迭治疗咳嗽变异性哮喘,疗效显著,缩短患者咳嗽缓解时间与症状消失时间,安全性较好,值得临床推荐。
Objective To investigate the clinical efficacy of montelukast combined with seretide in the treatment of cough variant asthma（ CVA）. Methods 96 CVA patients,who were admitted to hospital from October,2013 to October,2014 in accordance with random number table,were divided into observation group and control group with 48 cases in each group. The observation group were given montelukast combined with seretide while the control group were given inhaled seretide. The clinical efficacy of both groups were compared one month after treatment. Results The clinical efficacy of the observation group was significantly better than that of the control group,so difference was statistically significant（ P〈 0. 01）. Relief time of clinical symptoms and symptoms disappearance time of the observation group were significantly shorter than those of the control group（ P〈 0. 01）. Conclusion The effect of montelukast combined with seretide in the treatment of CVA is remarkable. It can shorten the relief time of cough and symptoms disappearance time,and it is safe for the patients. Thus,it is worthy of being recommended in clinic.
出处
《右江医学》
2015年第4期457-459,共3页
Chinese Youjiang Medical Journal
